YRYejing Rong

Yejing Rong

*This is an algorithmically generated author record based on publicly available information.

Yejing Rong has a total of 12 co-authors. Here are the top co-authors by number of shared publications:

  • Chunyan Ruan

    Department of Experimental Medical Science, Ningbo, China

    1 shared publication
  • Hua Wang

    Department of Experimental Haematology, Beijing Institute of Radiation Medicine, Beijing, China

    1 shared publication
  • Jiachang Jin

    Jiangbei Center For Disease Control and Prevention Ningbo, Ningbo, China

    1 shared publication
  • Jianping Zhu

    Department of Pharmacy, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China

    1 shared publication
  • Pei Feng

    Ningbo Qianyang Talent Service Co., Ltd, Ningbo, China

    1 shared publication
  • Shun Zhang

    Ningbo No. 2 Hospital, Guoke Ningbo Life Science and Health Industry Research Institute, Ningbo 315099, China

    1 shared publication

Latest Publications

  • Open Access

    Oncolytic adenovirus encoding decorin and CD40 ligand inhibits tumor growth and liver metastasis via immune activation in murine colorectal tumor model

    by Yejing Rong, Yingjun Ning, Jianping Zhu, Pei Feng, Weixin Zhu, Xin Zhao, Zi Xiong, Chunyan Ruan, Jiachang Jin, Hua Wang, et al.

    Colorectal cancer (CRC) is the second common cause of cancer mortality worldwide, and it still lacks effective approaches for relapsed and metastatic CRC. Recently, oncolytic virus has been emerged as a promising immune therapeutic strategy. In this study, we develop a novel oncolytic adenovirus, rAd.mDCN.mCD40L, which drive oncolytic activity by telomerase reverse transcriptase promoter (TERTp). rAd.mDCN.mCD40L expressed both mouse genes of decorin (mDCN) and CD40 ligand (mCD40L), and produced effective cytotoxicity in both human and mouse CRC cells. Moreover, oncolytic adenovirus mediated mDCN over-expression inhibited Met expression in vitro. In CT26 subcutaneous tumor model, intratumorally delivery of oncolytic adenoviruses could inhibit tumor growth and liver metastasis, while mDCN and/or mCD40L armed oncolytic adenoviruses produced much more impressive responses. No obvious toxicity was detected in lung, liver and spleen. Moreover, mDCN and/or mCD40L armed oncolytic adenoviruses altered the immune state to activate anti-tumor responses, including increasing CD8+ T effector cells and CD4+ memory T cells, reducing MDSCs and Tregs in peripheral blood. Furthermore, mDCN and/or mCD40L armed oncolytic adenoviruses mediated mDCN and/or mCD40L expression in tumors, and up-regulated Th1 cytokines and reduced Th2 cytokines in tumors, which will be benefit for remodeling tumor microenvironment. Importantly, rAd.mDCN.mCD40L and rAd.mCD40L prevented tumor liver metastasis much more effectively than rAd.Null and rAd.mDCN. Therefore, rAd.mDCN.mCD40L and rAd.mCD40L are promising approaches for CRC therapy.